Polygenic Embryo Screening: Where Do We Stand? – ESHRE
European Society of Human Reproduction and Embryology (ESHRE) shared a post on LinkedIn:
“Polygenic Embryo Screening: Where Do We Stand?
Polygenic embryo screening (PES) can now assess IVF embryos for risks of heart disease, diabetes, schizophrenia and cancers. It’s already available, but highly controversial.
The disconnect: patients show strong interest – healthcare professionals have serious concerns.
Join this ESHRE webinar as international experts share new research on these diverging attitudes. Through focused presentations and panel discussion, we’ll explore:
- What drives patient demand vs. professional hesitation
- How views differ across cultures and demographics
- The implications for policy, education and patient care
Be part of shaping how we navigate this emerging frontier in hashtag#ReproductiveGenetics.
Date: 10 February 2026 | 17:00 CET
Find out more.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Oct 24, 2026, 16:33Clare Mansfield: Flowering Fertility Support Programme Was Independently Evaluated by Health Innovation Hub Ireland
-
Oct 24, 2026, 16:17Diana Tain: Vitrification May Affect Oocyte Resilience Without Causing Chromosomal Instability
-
Oct 24, 2026, 16:02Albert Irkaliev: Peptides and the Future of ART
-
Oct 24, 2026, 15:57Resa Nabor: A Filipino Woman’s Journey of Faith, Infertility, and Unwavering Love
-
Oct 24, 2026, 15:41Esther Eleboh: Comparison of IVF Ovarian Stimulation Protocols
-
Oct 23, 2026, 17:34Breast Cancer Awareness Month: Supporting Women Through Every Journey – Egg Donor and Surrogate Solutions
-
Oct 23, 2026, 17:28Demián Glujovsky: What Happens to Fertility Patients Between Visits?
-
Oct 23, 2026, 17:21Stephen Parker Ellington: Empathetic Fertility Care Can Scale, Even When Your Team Can’t
-
Oct 23, 2026, 17:16ACOG Releases New Guidance on the Use of GLP-1s in Pregnancy and Lactation